Skip to content

Laura Q.M. Chow

Seattle Cancer Care Alliance

2 papers in the Anchorcite directory, published between 2012 and 2015, cited 17,527 times in total.

ORCID profile

Research topics

Frequent co-authors

Papers

  1. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 9,473 citations

    BACKGROUND: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity. METHODS: In this randomized, open-label, international phase 3 study, we assigned patients with nonsquamous non-small-cell lung cancer (NSCLC) that had…

  2. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine · 2012 · 8,054 citations

    BACKGROUND: Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host's immune system. Blockade of interactions between PD-1 and PD-L1 enhances…

Metadata from OpenAlex (CC0).